Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Epilepsy ll: Types01:22

Epilepsy ll: Types

24
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
24
Seizures l: Introduction01:20

Seizures l: Introduction

27
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
27
Seizures: Classification01:13

Seizures: Classification

2.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
Seizures ll: Types01:19

Seizures ll: Types

23
Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
23
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Novel epilepsy treatments in clinical development.

Epilepsy & behavior : E&B·2026
Same author

Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.

Drugs·2026
Same author

Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs.

Epilepsia·2026
Same author

Novel pharmacological therapies in development.

Current opinion in neurology·2026
Same author

Epilepsy, neuroinflammation and cannabidiol What do we know thus far?

Frontiers in pharmacology·2026
Same author

Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity.

Neurology·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
查看所有相关文章

相关实验视频

Updated: Apr 23, 2026

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research
04:41

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research

Published on: October 13, 2023

2.1K

:新的进展.

Solomon L Moshé1, Emilio Perucca2, Philippe Ryvlin3

  • 1Saul R Korey Department of Neurology, Dominick P Purpura Department of Neuroscience and Department of Pediatrics, Laboratory of Developmental Epilepsy, Montefiore/Einstein Epilepsy Management Center, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, NY, USA.

Lancet (London, England)
|September 28, 2014
PubMed
概括
此摘要是机器生成的。

影响全球数以百万计的人,导致残疾和高成本. 尽管在理解和治疗方面取得了进展,但许多患者仍然对治疗有抗性,这凸显了护理和研究中的关键差距.

更多相关视频

Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K

相关实验视频

Last Updated: Apr 23, 2026

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research
04:41

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research

Published on: October 13, 2023

2.1K
Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K

科学领域:

  • 神经学 神经学
  • 临床医学 临床医学
  • 公共卫生 公共卫生

背景情况:

  • 影响全球6500万人,在残疾,死亡率,并发性疾病,耻辱和经济负担方面带来了重大挑战.
  • 近几十年来,人们在了解的病理生理学和预后因素方面取得了进展.
  • 这导致了的更新定义,诊断标准和分类系统.

研究的目的:

  • 审查当前管理的现状,并确定持续存在的挑战.
  • 突出了解和治疗方面的进步,同时承认尚未满足的需求.

主要方法:

  • 对研究和临床实践近期进展的文献综述.
  • 对抗药物和外科手术治疗结果的分析.
  • 评估现有的知识,诊断,治疗和患者支持方面的差距.

主要成果:

  • 尽管20年来抗药物的使用量大幅增加,但大约三分之一的患者表现出耐药性.
  • 手术为一半以上的患者提供了显著的发作自由,但未得到充分利用.
  • 在知识,诊断,治疗,宣传,教育,立法和研究方面仍然存在持续的差距.

结论:

  • 在治疗,特别是耐药病例方面,仍然存在重大挑战.
  • 目前的治疗方式,包括手术,并没有达到所有符合条件的患者.
  • 迫切需要采取协调一致的行动,以应对治疗和研究中的多方面的挑战.